Personalized Treatment for Refractory H Pylori Infection
Helicobacter Pylori Infection
About this trial
This is an interventional treatment trial for Helicobacter Pylori Infection focused on measuring Helicobacter pylori, third-line therapy, antibiotic susceptibility, Eradication
Eligibility Criteria
Inclusion Criteria:
H pylori-infected adult patients with at least two previous failed eradication attempts will be enrolled in this study after giving informed consent.
- positive results of both rapid urease test and histology,
- a positive result of Urea breath test,
- or a positive result of culture
Exclusion Criteria:
- ingestion of antibiotics, bismuth, or proton-pump inhibitor within the prior 4 weeks,
- patients with allergic history to the medications used,
- patients with previous gastric surgery,
- the coexistence of serious concomitant illness (for example, decompensated liver cirrhosis, uremia),
- pregnant women.
Sites / Locations
- Kaohsiung Veterans General HospitalRecruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Experimental
Experimental
Active Comparator
rabeprazole+3 antibiotics
rabeprazole+bismuth+2 antibiotics
rabeprazole+amox+tetr+levo
patients who have positive result of culture with equal to or more than three susceptible antibiotics are treated by non-bismuth quadruple therapy (rabeprazole 20 mg q.d.s. and three effective antibiotics) for 14 days
patients who have positive result of culture with one or two susceptible antibiotics are treated by bismuth-containing therapy (rabeprazole 20 mg q.d.s., bismuth subcitrate 120 mg q.d.s. and all the effective antibiotics) for 14 days
patients who have negative result of culture or whose culture data are unavailable will be treated by (rabeprazole 20 mg q.d.s, amoxicillin 500 mg q.d.s., tetracycline 500 mg q.d.s. and levofloxacin 500 mg o.d.) for 14 days